search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
BIOTECHNOLOGY


The Xvivo system achieves complete closure, complete avoidance of air


and virtually no limits or constraints up-front or over time


systems (SUS), which have exploded in use. Keeping cells aseptic inside a pre-sterilised bag, bag/tube assembly or cassette is easy. Tere is less cleaning and virtually no biocide needed. Add to that the productive functionality of their associated mechanical devices, including and up to full automation, and it explains why these closed SUS devices are a dominant trend in modernisation. Some are uni-function SUS devices, designed for one step in production (e.g. cell separation). Some are multi-function SUS devices that do several steps (e.g. cell washing and dilution). Some actually do all the steps in production, and are fully automated (toti-function SUS devices). One of the most commercially successful is toti-function SUS devices designed for automated production of CAR-T cell cancer therapies. Although limited to one specific process, these are truly modern marvels. However, they don’t necessarily


produce the best or most cells. Recent comparability studies from the NIH show surprising results. Although the exposure to air is assumed to be minimal, it is not clear how well exposures to suboptimal transients of the critical process parameters temperature, CO2 O2


are avoided. Other variables inherent to each fixed SUS platform might also be


suboptimal and significantly influence the final cell product.


“Tis is the challenge with standardised


live cell process automation. Whether it is one step, or a few steps, or all the steps in production, an automated process that doesn’t degrade one kind of cell may degrade others,” explains Yerden. “Automating too early in development is a risk. Only clinical trials can tell if the cell product works. Developers need flexibility


until clinical trials prove successful, and canned automation is not usually flexible. “In development, only comparability studies can tell if a process change, such as automation, improves or hurts product quality. Tus uni-function SUS devices and multi-function SUS devices impose less risk because they do not automate the entire process, but then upstream and downstream steps may still be left exposed to air,” adds Yerden.


and Instead of air inside, it is filled with a mix of gases from tanks www.scientistlive.com 33


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60